千红制药
(002550)
| 流通市值：58.44亿 | | | 总市值：82.16亿 |
| 流通股本：9.10亿 | | | 总股本：12.80亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,207,602,942.05 | 855,595,853.5 | 461,101,487.65 | 1,814,268,908.89 |
| 营业收入 | 1,207,602,942.05 | 855,595,853.5 | 461,101,487.65 | 1,814,268,908.89 |
| 二、营业总成本 | 957,440,753.08 | 654,233,631.46 | 344,356,267.11 | 1,666,045,224.07 |
| 营业成本 | 555,283,016.54 | 404,710,259.39 | 216,068,845.29 | 1,029,333,504.43 |
| 税金及附加 | 19,118,814.27 | 13,062,762.82 | 6,387,200.36 | 20,402,904.09 |
| 销售费用 | 237,447,737.71 | 157,478,662.65 | 78,393,143.31 | 393,856,856.88 |
| 管理费用 | 85,931,181.56 | 51,845,727.06 | 26,160,279.72 | 131,760,590.33 |
| 研发费用 | 60,923,369.71 | 31,889,577.88 | 17,478,054.22 | 97,083,446.01 |
| 财务费用 | -1,263,366.71 | -4,753,358.33 | -131,255.79 | -6,392,077.67 |
| 其中:利息费用 | 1,172,924.53 | 982,019.35 | 726,667.2 | 5,926,399.35 |
| 其中:利息收入 | 5,969,694.38 | 6,212,062.57 | 2,018,292.95 | 11,298,061.13 |
| 加:公允价值变动收益 | 1,280,070.99 | 858,805.13 | 430,734.45 | 771,381.2 |
| 加:投资收益 | 5,156,866.58 | 549,372.2 | 3,028,237.13 | 8,004,545.03 |
| 资产处置收益 | - | 0 | - | 25,350,482.59 |
| 资产减值损失(新) | 49,648.14 | 49,648.14 | - | -19,616,130.84 |
| 信用减值损失(新) | 81,940,746.89 | -3,620,961.39 | -6,064,766.43 | 17,427,467.13 |
| 其他收益 | 8,382,086.13 | 5,352,521.17 | 2,868,043.79 | 24,195,093.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 346,971,607.7 | 204,551,607.29 | 117,007,469.48 | 204,356,523.6 |
| 加:营业外收入 | 1,347,442.09 | 1,118,873.73 | 1,829.56 | 350,921.88 |
| 减:营业外支出 | 619,459.23 | 231,203.05 | 174,400.14 | 1,183,966.55 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 347,699,590.56 | 205,439,277.97 | 116,834,898.9 | 203,523,478.93 |
| 减:所得税费用 | 49,101,668.66 | 29,011,961.94 | 15,488,195.37 | 24,851,439.77 |
| 六、净利润 | 298,597,921.9 | 176,427,316.03 | 101,346,703.53 | 178,672,039.16 |
| 持续经营净利润 | 298,597,921.9 | 176,427,316.03 | 101,346,703.53 | 178,672,039.16 |
| 归属于母公司股东的净利润 | 309,585,156.72 | 182,792,344.63 | 104,108,160.35 | 181,860,747.32 |
| 少数股东损益 | -10,987,234.82 | -6,365,028.6 | -2,761,456.82 | -3,188,708.16 |
| (一)基本每股收益 | 0.25 | 0.15 | 0.08 | 0.14 |
| (二)稀释每股收益 | 0.25 | 0.15 | 0.08 | 0.14 |
| 八、其他综合收益 | 139,702.95 | -741,724.96 | -1,322,708.98 | 420,502.44 |
| 归属于母公司股东的其他综合收益 | 139,702.95 | -741,724.96 | -1,322,708.98 | 420,502.44 |
| 九、综合收益总额 | 298,737,624.85 | 175,685,591.07 | 100,023,994.55 | 179,092,541.6 |
| 归属于母公司股东的综合收益总额 | 309,724,859.67 | 182,050,619.67 | 102,785,451.37 | 182,281,249.76 |
| 归属于少数股东的综合收益总额 | -10,987,234.82 | -6,365,028.6 | -2,761,456.82 | -3,188,708.16 |
| 公告日期 | 2024-10-18 | 2024-08-16 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |